Fund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...

A new study presented at ENDO 2026 has found that male rats exposed to the common plastic chemical di-(2-ethylhexyl) phthalate (DEHP) durin...

Formula 1 is focusing on India as a key market. The sport's chief executive sees potential for a return to India. Adani Group is actively w...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

Households with at least one user of GLP-1 weight-loss drugs bought 299 million fewer food items in the year after adoption of the medicati...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...

Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...

Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This onc...

The notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the...

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...